rs113488022
|
|
Tumor Progression
|
|
0.100 |
GeneticVariation
|
BEFREE |
It is assumed that BRAF(V600E) may not confer growth advantage on paediatric PTCs, and many of these cases grow slowly, suggesting that additional factors may be important for tumour progression in paediatric PTCs.
|
26584635 |
2015 |
rs113488022
|
|
Tumor Progression
|
|
0.100 |
GeneticVariation
|
BEFREE |
Beyond development, we can look into the effectiveness of already approved targeted therapies (eg, anti-BRAF(V600E) selective inhibitors, tyrosine kinase inhibitors, histone deacetylase inhibitors, inhibitors of DNA methylation, etc) to potentially test in ATC after learning the molecular mechanisms that aid in tumor progression.
|
25347569 |
2015 |
rs113488022
|
|
Tumor Progression
|
|
0.100 |
GeneticVariation
|
BEFREE |
Correspondingly, in established murine BRAF(V600E)-driven nevi, acute shRNA-mediated depletion of PTEN prompted tumor progression.
|
22549727 |
2012 |
rs121913529
|
|
Tumor Progression
|
|
0.050 |
GeneticVariation
|
BEFREE |
To determine which KRAS effectors were responsible for tumor progression, we created four effector domain mutants (S35, G37, E38 and C40) in G12V-activated KRAS and expressed these alone or with BrafV600E in mouse lungs...
|
24489653 |
2014 |
rs121913529
|
|
Tumor Progression
|
|
0.050 |
GeneticVariation
|
BEFREE |
Co-expression of Kras(G12V) and Braf(D631A) in mouse lung cells markedly enhances tumour initiation, a phenomenon mediated by Craf kinase activity, and effectively accelerates tumour progression when activated in advanced lung adenocarcinomas.
|
28783725 |
2017 |
rs121913529
|
|
Tumor Progression
|
|
0.050 |
GeneticVariation
|
BEFREE |
We hypothesized that tumor progression was because of concomitant activation of the mitogen-activated protein kinase pathway downstream of Kras(G12D) expression promoting cell survival and that the therapeutic effect of PF-04691502 would be enhanced by combinatory inhibition of MEK using PD-0325901.
|
21632463 |
2011 |
rs121913529
|
|
Tumor Progression
|
|
0.050 |
GeneticVariation
|
BEFREE |
The transformed phenotype of IOE(CMYC) cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOE(CMYC) cells had undergone morphological and phenotypic changes characteristic of neoplastic progression.
|
21859834 |
2011 |
rs121913529
|
|
Tumor Progression
|
|
0.050 |
GeneticVariation
|
BEFREE |
Other organs such as pancreas, liver, and small intestine do not exhibit neoplastic progression within 6 weeks following K-Ras(G12D) activation and do not show a potent tumor suppressor response.
|
22532587 |
2012 |
rs121434569
|
|
Tumor Progression
|
|
0.040 |
GeneticVariation
|
BEFREE |
Detection of T790M with plasma DNA was correlated with EGFR mutation type, exon 19 deletions and tumor progression.
|
26577492 |
2016 |
rs121434569
|
|
Tumor Progression
|
|
0.040 |
GeneticVariation
|
BEFREE |
The EGFR resistance mutation T790M should be monitored at cancer progression.
|
31445213 |
2019 |
rs121434569
|
|
Tumor Progression
|
|
0.040 |
GeneticVariation
|
BEFREE |
Liquid biopsies (LB) are used routinely in clinical practice in two situations for late stage non-small-cell lung cancer (NSCLC) patients, (i) at the initial diagnosis when looking for activating mutations in EGFR in the absence of analyzable tissue DNA and, (ii) during tumor progression on a tyrosine kinase inhibitor treatment to look for the resistance mutation T790M in EGFR.
|
29069959 |
2017 |
rs121434569
|
|
Tumor Progression
|
|
0.040 |
GeneticVariation
|
BEFREE |
Finally, in the prospective series, SiRe detected 8.7% (4/46) of EGFR mutations at baseline and 42.9% (9/21) of EGFR p.T790M in patients at tumour progression.
|
28170370 |
2017 |
rs758272654
|
|
Tumor Progression
|
|
0.030 |
GeneticVariation
|
BEFREE |
In summary, the GNAS1 T393C SNP represents a genetic host factor for predicting tumor progression also in patients with MM; genotyping of this SNP may contribute to better define patients who could benefit from an early individualized therapy.
|
21156401 |
2010 |
rs758272654
|
|
Tumor Progression
|
|
0.030 |
GeneticVariation
|
BEFREE |
The present study provides strong evidence to suggest that the GNAS1 T393C allele carrier status influences tumor progression and survival in gastric cancer with higher tumor stages and a worse outcome for C allele carriers.
|
20027678 |
2009 |
rs758272654
|
|
Tumor Progression
|
|
0.030 |
GeneticVariation
|
BEFREE |
Kaplan-Meier curves for tumor progression, development of metastasis, and tumor-related death showed a significant association of the T393C polymorphism with outcome (5-year cancer-specific survival rates: TT, 91%; TC, 81%; CC, 69%; P = 0.015).
|
16467086 |
2006 |
rs351855
|
|
Tumor Progression
|
|
0.030 |
GeneticVariation
|
BEFREE |
Three other nonparametric linear rank-tests particularly suitable for investigating possible relations between G388R mutation and early cancer progression were also used.
|
14710228 |
2004 |
rs351855
|
|
Tumor Progression
|
|
0.030 |
GeneticVariation
|
BEFREE |
Thus, our findings elucidate the molecular mechanism behind the genetic association of rs351855 with accelerated cancer progression and suggest that germline variants of cell-surface molecules that recruit STAT3 to the inner cell membrane are a significant risk for cancer prognosis and disease progression.
|
26675719 |
2015 |
rs351855
|
|
Tumor Progression
|
|
0.030 |
GeneticVariation
|
BEFREE |
This LOH involved the FGFR4-WT allele as frequently as the cancer progression-associated FGFR4-G388R polymorphic allele.
|
21037081 |
2010 |
rs762846821
|
|
Tumor Progression
|
|
0.020 |
GeneticVariation
|
BEFREE |
The concomitant expression of oncogenic Kras(G12D) and mutant p53 (Trp53(R172H)) in the murine pancreas results in metastatic PDA that recapitulates the cognate features of human pancreatic cancer providing an excellent animal model to identify genes required for tumor progression.
|
22158044 |
2012 |
rs762846821
|
|
Tumor Progression
|
|
0.020 |
GeneticVariation
|
BEFREE |
We crossed IL-6(-/-) mice with Kras(G12D) mutant mice, which develop lung tumors after activation of mutant Kras(G12D), to investigate whether IL-6 inhibition contributes to tumor progression and survival time in vivo.
|
24260500 |
2013 |
rs752021744
|
|
Tumor Progression
|
|
0.020 |
GeneticVariation
|
BEFREE |
Additionally, we tested efficacy of PD-0325901 in Kras(G12D-LSL) conditional GEMMs (genetically engineered mouse models) which are a valuable tool in translational research to study tumor progression.
|
22684718 |
2012 |
rs752021744
|
|
Tumor Progression
|
|
0.020 |
GeneticVariation
|
BEFREE |
We hypothesized that tumor progression was because of concomitant activation of the mitogen-activated protein kinase pathway downstream of Kras(G12D) expression promoting cell survival and that the therapeutic effect of PF-04691502 would be enhanced by combinatory inhibition of MEK using PD-0325901.
|
21632463 |
2011 |
rs3761548
|
|
Tumor Progression
|
|
0.020 |
GeneticVariation
|
BEFREE |
Stratified data also revealed an association of homozygous mutant genotype with advanced stage of tumor in premenopausal women (OR = 4.56; 95% CI = 1.07-19.38; p = 0.04) with disease duration of <6 months (OR = .10; 95% CI = 1.80-20.50; p = 0.002) suggestive of modulating effect of rs3761548 in tumor progression.
|
24338714 |
2014 |
rs3761548
|
|
Tumor Progression
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our study suggests that <i>FOXP3</i> polymorphism rs3761548 is associated with BC susceptibility in the Chinese and may be involved in tumor progression.
|
29731666 |
2018 |
rs2273535
|
|
Tumor Progression
|
|
0.020 |
GeneticVariation
|
BEFREE |
The single nucleotide polymorphism AURKA T91A (rs2273535) (Phe21Ile) has been identified as functional alternator of this kinase, the Ile allele is associated with the occurrence of chromosome segregation errors and tumor progression.
|
28647900 |
2018 |